ANALYSIS OF GP39/CD40 INTERACTIONS USING MOLECULAR-MODELS AND SITE-DIRECTED MUTAGENESIS

被引:56
作者
BAJORATH, J [1 ]
MARKEN, JS [1 ]
CHALUPNY, NJ [1 ]
SPOON, TL [1 ]
SIADAK, AW [1 ]
GORDON, M [1 ]
NOELLE, RJ [1 ]
HOLLENBAUGH, D [1 ]
ARUFFO, A [1 ]
机构
[1] DARTMOUTH COLL SCH MED,DEPT MICROBIOL,LEBANON,NH 03756
关键词
D O I
10.1021/bi00031a009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The interaction between gp39 (CD40L, TRAP, T-BAM) on activated T cells and mast cells and CD40 on antigen-presenting cells modulates immune responses. Gp39 and CD40 are homologous to tumor necrosis factor (TNF) and its receptor (TNFR), respectively. The TNF-beta/TNFR interaction has been analyzed on the basis of mutagenesis experiments and crystal structures. Using the interaction of TNF-beta/TNFR as a guide, we previously reported a site-directed mutagenesis study in which we identified residues in gp39 (K143, Y145) and CD40 (Y82, D84, N86) involved in gp39/CD40 interactions. Here we describe the use of the TNF-beta/TNFR complex crystal structure as a template to prepare molecular models of gp39, CD40, and their approximate interaction. The application of these models has allowed us to extend our mutagenesis analysis of gp39/CD40 interactions, These experiments have led to the identification of additional gp39 (Y146, R203, Q220) and CD40 (E74, E117) residues that contribute to the gp39/CD40 interaction. We also further explored the importance of gp39 residue Y145 and CD40 residue Y82 for the gp39/CD40 interaction by conservatively replacing these residues with Phe. The results of these studies have enabled us to approximately outline the binding sites in gp39 and CD40. It appears that the gp39/CD40 interaction is centered on at least two clusters of residues and involves residues of two adjacent gp39 monomers. The molecular regions involved in the gp39/CD40 interaction essentially correspond to those in the homologous TNF-beta/TNFR system.
引用
收藏
页码:9884 / 9892
页数:9
相关论文
共 38 条
[1]   CD40 EXPRESSION BY HUMAN MONOCYTES - REGULATION BY CYTOKINES AND ACTIVATION OF MONOCYTES BY THE LIGAND FOR CD40 [J].
ALDERSON, MR ;
ARMITAGE, RJ ;
TOUGH, TW ;
STROCKBINE, L ;
FANSLOW, WC ;
SPRIGGS, MK .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (02) :669-674
[2]   CD40 LIGAND GENE DEFECTS RESPONSIBLE FOR X-LINKED HYPER-IGM SYNDROME [J].
ALLEN, RC ;
ARMITAGE, RJ ;
CONLEY, ME ;
ROSENBLATT, H ;
JENKINS, NA ;
COPELAND, NG ;
BEDELL, MA ;
EDELHOFF, S ;
DISTECHE, CM ;
SIMONEAUX, DK ;
FANSLOW, WC ;
BELMONT, J ;
SPRIGGS, MK .
SCIENCE, 1993, 259 (5097) :990-993
[3]   MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF A MURINE LIGAND FOR CD40 [J].
ARMITAGE, RJ ;
FANSLOW, WC ;
STROCKBINE, L ;
SATO, TA ;
CLIFFORD, KN ;
MACDUFF, BM ;
ANDERSON, DM ;
GIMPEL, SD ;
DAVISSMITH, T ;
MALISZEWSKI, CR ;
CLARK, EA ;
SMITH, CA ;
GRABSTEIN, KH ;
COSMAN, D ;
SPRIGGS, MK .
NATURE, 1992, 357 (6373) :80-82
[4]   THE CD40 LIGAND, GP39, IS DEFECTIVE IN ACTIVATED T-CELLS FROM PATIENTS WITH X-LINKED HYPER-IGM SYNDROME [J].
ARUFFO, A ;
FARRINGTON, M ;
HOLLENBAUGH, D ;
LI, X ;
MILATOVICH, A ;
NONOYAMA, S ;
BAJORATH, J ;
GROSMAIRE, LS ;
STENKAMP, R ;
NEUBAUER, M ;
ROBERTS, RL ;
NOELLE, RJ ;
LEDBETTER, JA ;
FRANCKE, U ;
OCHS, HD .
CELL, 1993, 72 (02) :291-300
[5]   KNOWLEDGE-BASED MODEL-BUILDING OF PROTEINS - CONCEPTS AND EXAMPLES [J].
BAJORATH, J ;
STENKAMP, R ;
ARUFFO, A .
PROTEIN SCIENCE, 1993, 2 (11) :1798-1810
[6]   IDENTIFICATION OF RESIDUES ON CD40 AND ITS LIGAND WHICH ARE CRITICAL FOR THE RECEPTOR-LIGAND INTERACTION [J].
BAJORATH, J ;
CHALUPNY, NJ ;
MARKEN, JS ;
SIADAK, AW ;
SKONIER, J ;
GORDON, M ;
HOLLENBAUGH, D ;
NOELLE, RJ ;
OCHS, HD ;
ARUFFO, A .
BIOCHEMISTRY, 1995, 34 (06) :1833-1844
[7]  
BAJORATH J, 1992, IMMUNOMETHODS, V1, P137
[8]   CRYSTAL-STRUCTURE OF THE SOLUBLE HUMAN 55 KD TNF RECEPTOR-HUMAN TNF-BETA COMPLEX - IMPLICATIONS FOR TNF RECEPTOR ACTIVATION [J].
BANNER, DW ;
DARCY, A ;
JANES, W ;
GENTZ, R ;
SCHOENFELD, HJ ;
BROGER, C ;
LOETSCHER, H ;
LESSLAUER, W .
CELL, 1993, 73 (03) :431-445
[9]   UNRAVELING FUNCTION IN THE TNF LIGAND AND RECEPTOR FAMILIES [J].
BEUTLER, B ;
VANHUFFEL, C .
SCIENCE, 1994, 264 (5159) :667-668
[10]  
Bruccoleri R. E., 1992, IMMUNOMETHODS, V1, P96